Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell development

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,206 result(s) found for: Cell development. Displaying page 1 of 61.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-000243-10 Sponsor Protocol Number: Hx-CD20-407 Start Date*: 2007-05-16
    Sponsor Name:Glaxo SmithKline Research and Development Limited
    Full Title: An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previ...
    Medical condition: B-cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-004568-37 Sponsor Protocol Number: INV543 Start Date*: 2018-11-30
    Sponsor Name:Nova Laboratories Limited
    Full Title: A prospective open label, pharmacokinetic study of an oral hydroxyurea solution in children with sickle cell anemia
    Medical condition: Sickle Cell Anaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    20.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000104-42 Sponsor Protocol Number: U31287-A-U201E Start Date*: 2013-06-14
    Sponsor Name:DAIICHI SANKYO DEVELOPMENT LTD.
    Full Title: Open-label, Non-randomized Study of U3-1287 in Combination with Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC) - Extension
    Medical condition: Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000388-10 Sponsor Protocol Number: RF-2010-2318192 Start Date*: 2013-03-30
    Sponsor Name:AZIENDA ULSS N.9 - TREVISO, UOC PEDIATRIA
    Full Title: Oral steroids for reducing renal scarring in infants with febrile urinary tract infections at high risk for renal scar development: a randomized controlled trial
    Medical condition: Infants with febrile UTI at higher risk for renal scar development based on PCT values ≥ 1 ng/mL
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016083-36 Sponsor Protocol Number: CS7017-A-U204 Start Date*: 2010-10-21
    Sponsor Name:Daiichi Sankyo Pharma Development
    Full Title: Phase 2 Study of CS-7017 and Erlotinib in Subjects with Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy
    Medical condition: Treatment of patients with advanced non-small cell lung cancer (NSCLC) after failure of prior chemotherapy regimen
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025054 Lung cancer non-small cell stage IIIB LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004944-30 Sponsor Protocol Number: AFX01-06 Start Date*: 2006-02-23
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
    Medical condition: Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10002965 Aplasia pure red cell PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003356-30 Sponsor Protocol Number: M18-007 Start Date*: 2014-12-09
    Sponsor Name:OncoMed Pharmaceuticals, Inc.
    Full Title: A 3-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo versus Carboplatin, Pemetrexed plus 1 or 2 Truncated Courses of Demcizumab in Subjects with Non-Squamous Non-Sm...
    Medical condition: Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005289-32 Sponsor Protocol Number: GBT2104-133 Start Date*: 2021-11-10
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004225-24 Sponsor Protocol Number: PCI-32765CAN3001 Start Date*: 2013-01-15
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
    Medical condition: chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) SE (Completed) BE (Trial now transitioned) IE (Completed) PT (Trial now transitioned) HU (Completed) NL (Ongoing) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003884-25 Sponsor Protocol Number: 4202-HEM-301 Start Date*: 2021-06-07
    Sponsor Name:Forma Therapeutics, Inc.
    Full Title: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
    Medical condition: sickle cell disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Temporarily Halted) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005115-32 Sponsor Protocol Number: 213824 Start Date*: 2022-09-16
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Prog...
    Medical condition: Non-small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004839-25 Sponsor Protocol Number: BO42451 Start Date*: 2021-08-18
    Sponsor Name:F. HOFFMANN - LA ROCHE LTD.
    Full Title: A RANDOMIZED DOUBLE-BLIND PHASE IIA STUDY EVALUATING THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB AS ADJUNCT TREATMENT IN PREVENTION OF VASO-OCCLUSIVE EPISODES (VOE) I...
    Medical condition: Sickle Cell Disease (SCD); vaso-occlusive episodes in SCD
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    20.0 100000004851 10072397 Vaso-occlusive crisis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021082-74 Sponsor Protocol Number: U31287-A-U201 Start Date*: 2011-01-21
    Sponsor Name:DAIICHI SANKYO DEVELOPMENT LTD.
    Full Title: RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 1B/2 STUDY OF U3-1287 (AMG 888) IN COMBINATION WITH ERLOTINIB IN EGFR TREATMENT NAÏVE SUBJECTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WH...
    Medical condition: Treatment for advanced or metastatic NSCLC in combination with erlotinib in subjects who are epidermal growth factor receptor (EGFR) treatment naïve after failure of at least one prior chemotherapy...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) LT (Completed) HU (Completed) GB (Completed) BG (Completed) AT (Completed) SI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001623-18 Sponsor Protocol Number: EGF102988 Start Date*: 2006-12-07
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or P...
    Medical condition: Resected Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041823 Squamous cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IE (Completed) GR (Completed) AT (Completed) SK (Completed) GB (Completed) DE (Completed) CZ (Completed) PT (Prematurely Ended) EE (Completed) HU (Completed) IT (Completed) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002579-83 Sponsor Protocol Number: 54767414LUC2001 Start Date*: 2017-02-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic N...
    Medical condition: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029521 Non-small cell lung cancer stage IIIB PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005637-47 Sponsor Protocol Number: ESR-14-10637 Start Date*: 2017-04-27
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Randomized study of AZD9291 treatment of EGFR M+ NSCLC patients progressing on first line erlotinib. A study based upon detection of EGFR M+ ctDNA in plasma and urine.
    Medical condition: Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003012-35 Sponsor Protocol Number: HM07/8281 Start Date*: 2012-06-12
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CL...
    Medical condition: Chronic lymphocytic leukaemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000779-40 Sponsor Protocol Number: VEG109611 Start Date*: 2008-07-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Phase II Trial of Pazopanib, a Pan Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitor, in Relapsed or Refractory Small Cell Lung Cancer (SCLC)
    Medical condition: Relapsed or Refractory Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041067 Small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005267-48 Sponsor Protocol Number: 4202-HEM-201 Start Date*: 2022-10-17
    Sponsor Name:FORMA THERAPEUTICS, INC.
    Full Title: A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell Disease
    Medical condition: Sickle cell disease (SCD) or thalassemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004850 10040646 Sickle cell disorders LLT
    20.1 100000004850 10040649 Sickle cell thalassaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:06:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA